XML 58 R36.htm IDEA: XBRL DOCUMENT v3.26.1
Note 1 - Nature of the Business (Details Textual)
$ / shares in Units, ¥ in Millions
1 Months Ended 12 Months Ended
Jan. 24, 2025
USD ($)
Jul. 03, 2019
Sep. 30, 2025
USD ($)
$ / shares
shares
Jan. 31, 2025
USD ($)
Aug. 31, 2024
USD ($)
$ / shares
shares
Jul. 03, 2019
USD ($)
Jul. 03, 2019
CNY (¥)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2019
CNY (¥)
Capital contribution from noncontrolling interests               $ 2,720,000 $ 20,000,000    
Stock Issued During Period, Value, New Issues               $ 1,980,000 $ 2,970,000    
Seed [Member]                      
Proceeds from Sale, Maturity and Collection of Investments $ 35,418     $ 35,418,000              
Series A-3 Preferred Stock [Member] | Series A-3 Financing [Member] | Seed [Member]                      
Stock Issued During Period, Shares, New Issues | shares     1,411,761   5,647,059            
Stock Issued During Period, Value, New Issues     $ 6,000   $ 24,000            
Shares Issued, Price Per Share | $ / shares     $ 4.25   $ 4.25            
Wanchunbulin [Member]                      
Investment Agreement Amount           $ 14,537,000 ¥ 100        
Proceeds From Noncontrolling Interest, Percent   4.76%                  
Capital contribution from noncontrolling interests                   $ 10,083,000 ¥ 70
SEED Therapeutics Inc. [Member]                      
Ownership Percentage in Subsidiaries       13.62%       36.61%      
Seed [Member]                      
Ownership Percentage in Subsidiaries     34.29%